

1987 INDEX

A

- Absorptiometry (*see* Photon absorp-
tometry)
- Acquired immunodeficiency syn-
drome (*see* AIDS)
- Additives: causing anaphylaxis, Aug.
454
- Adenylate cyclase regulation: by G
proteins, mechanism of, Dec.
700
- ADFR approach: to osteoporosis
therapy, Oct. 587
- Adrenal-hypothalamic-pituitary axis:
in shock, June 330-331
- Adrenergic
agents in shock, June 344-347
receptors
 α -, June 322
 selectivity of catecholamines
 for, June 324
in shock, June 321-324
- Age
 advancing, bone mass changes
 with, Oct. 549
 pulmonary disease and, drug-in-
 duced, Feb. 83
 -related bone loss, pathophysi-
 ogy, Oct. 551-555
- AIDS, Apr. 223-230
 approach to high risk patient,
 Apr. 227-229
 contacts, Apr. 228-229
 epidemiology, Apr. 223-225
 identification, Apr. 226-227
 Kaposi's sarcoma in, Apr. 218
 management, Apr. 226-227
 patients at risk, Apr. 228-229
 physical examination, Apr. 225-
 226
 pneumonia etiologies in, Jan. 42
 pulmonary complications, Jan.
 41-43
 risk factors, Apr. 223-225
 symptoms, Apr. 225-226
- Alcohol
 epilepsy and, Nov. 663, 665
 intoxication causing seizures,
 Nov. 640
 osteoporosis and, Oct. 576
 withdrawal causing seizures, Nov.
 640-641
- Alcoholism: and osteoporosis, Oct.
562-563
- Aldosterone-renin-angiotensin axis:
in shock, June 325-326
- Amiodarone (*see* Pulmonary dis-
ease, amiodarone-induced)
- Anaphylactic reactions: causing
shock, June 336-337
- Anaphylactoid reactions: causing
shock, June 336-337
- Anaphylaxis, Aug. 441-479
 additives causing, Aug. 454
 anesthesia causing, Aug. 453
 duration of resuscitation, Aug.
 457
 local, Aug. 454
 antibiotics causing, Aug. 452
 antibodies in, Aug. 443-444
 antihistamines in, Aug. 467
 arrhythmias during, Aug. 461
 aura in, Aug. 457
 bronchospasm in, Aug. 459
 treatment, Aug. 467-468
 cardiovascular collapse in, Aug.
 459-462
 cardiac filling pressures in,
 Aug. 461
 ECG changes in, Aug. 461
 causes, Aug. 451-456
 nonpharmacologic, Aug. 455-
 456
 chymopapain causing, Aug. 453
 clinical features, Aug. 457-462
 major, Aug. 458-462
 minor, Aug. 457-458
 colloid solutions causing, Aug.
 454
 complement system in, Aug. 445
 contrast media causing, Aug. 452-
 453
 desensitization and, Aug. 474
 diagnosis, Aug. 469-472

1987 INDEX

A

- Absorptiometry (*see* Photon absorp-
tometry)
- Acquired immunodeficiency syn-
drome (*see* AIDS)
- Additives: causing anaphylaxis, Aug.
454
- Adenylate cyclase regulation: by G
proteins, mechanism of, Dec.
700
- ADFR approach: to osteoporosis
therapy, Oct. 587
- Adrenal-hypothalamic-pituitary axis:
in shock, June 330-331
- Adrenergic
agents in shock, June 344-347
receptors
 α -, June 322
 selectivity of catecholamines
 for, June 324
in shock, June 321-324
- Age
 advancing, bone mass changes
 with, Oct. 549
 pulmonary disease and, drug-in-
 duced, Feb. 83
 -related bone loss, pathophysi-
 ogy, Oct. 551-555
- AIDS, Apr. 223-230
 approach to high risk patient,
 Apr. 227-229
 contacts, Apr. 228-229
 epidemiology, Apr. 223-225
 identification, Apr. 226-227
 Kaposi's sarcoma in, Apr. 218
 management, Apr. 226-227
 patients at risk, Apr. 228-229
 physical examination, Apr. 225-
 226
 pneumonia etiologies in, Jan. 42
 pulmonary complications, Jan.
 41-43
 risk factors, Apr. 223-225
 symptoms, Apr. 225-226
- Alcohol
 epilepsy and, Nov. 663, 665
 intoxication causing seizures,
 Nov. 640
 osteoporosis and, Oct. 576
 withdrawal causing seizures, Nov.
 640-641
- Alcoholism: and osteoporosis, Oct.
562-563
- Aldosterone-renin-angiotensin axis:
in shock, June 325-326
- Amiodarone (*see* Pulmonary dis-
ease, amiodarone-induced)
- Anaphylactic reactions: causing
shock, June 336-337
- Anaphylactoid reactions: causing
shock, June 336-337
- Anaphylaxis, Aug. 441-479
 additives causing, Aug. 454
 anesthesia causing, Aug. 453
 duration of resuscitation, Aug.
 457
 local, Aug. 454
 antibiotics causing, Aug. 452
 antibodies in, Aug. 443-444
 antihistamines in, Aug. 467
 arrhythmias during, Aug. 461
 aura in, Aug. 457
 bronchospasm in, Aug. 459
 treatment, Aug. 467-468
 cardiovascular collapse in, Aug.
 459-462
 cardiac filling pressures in,
 Aug. 461
 ECG changes in, Aug. 461
 causes, Aug. 451-456
 nonpharmacologic, Aug. 455-
 456
 chymopapain causing, Aug. 453
 clinical features, Aug. 457-462
 major, Aug. 458-462
 minor, Aug. 457-458
 colloid solutions causing, Aug.
 454
 complement system in, Aug. 445
 contrast media causing, Aug. 452-
 453
 desensitization and, Aug. 474
 diagnosis, Aug. 469-472

- communication and, Aug. 471-472
- determining agent responsible, Aug. 469-470
- determining mechanism, Aug. 470-471
- determining safe alternatives, Aug. 471
- differential, Aug. 463-464
- differential, after reaction, Aug. 463-464
- differential, during reaction, Aug. 463
- drugs causing, Aug. 452-455
 - anesthetic, Aug. 452
 - high-risk, avoidance of, Aug. 472
- drugs in, therapeutic, Aug. 465-467
 - experimental, Aug. 468-469
- edema in
 - angioneurotic, Aug. 458-459
 - generalized, Aug. 462
 - pulmonary, noncardiogenic, Aug. 462
- exercise-induced, Aug. 455
- foods causing, Aug. 455
- gastrointestinal symptoms in, Aug. 462
- histamine and, Aug. 449-451
- Hymenoptera causing, Aug. 455
- immunoglobulin in
 - A, Aug. 444
 - D, Aug. 444
 - E, Aug. 444
 - G, Aug. 443-444
 - M, Aug. 444
- latent period, Aug. 464
- mediators in, Aug. 444-445, 446
- natural history, Aug. 456-457
- osmotic reactions causing, Aug. 454
- pathophysiology, Aug. 448-451
 - animal data, Aug. 448-449
 - human data, Aug. 449-451
- physical stimuli causing, Aug. 455-456
- predisposing factors, Aug. 456
- preservatives causing, Aug. 454
- prevention, Aug. 472-474
 - in patient with history of reaction, Aug. 472-473
- protamine causing, Aug. 453-454
- reptiles causing, Aug. 455
- selection of at-risk patients, Aug. 472
- skin changes in, Aug. 457-458
- steroids causing, Aug. 454
- steroids in, therapeutic, Aug. 467
- sympathomimetics in, Aug. 465
- terminology, Aug. 442-443
- test dose, Aug. 474
- treatment, Aug. 464-469
 - nonspecific, Aug. 464-465
 - self-treatment, Aug. 474
- vehicles causing, Aug. 454
- Anesthesia (*see* Anaphylaxis, anesthesia causing)
- Angiography: in mitral valve prolapse, Sept. 511-516
- Angioneurotic edema: in anaphylaxis, Aug. 458-459
- Angiotensin-renin-aldosterone axis: in shock, June 325-326
- Antiarrhythmic
 - agents, July 384-386
 - action, cellular basis of, July 384-385
 - clinical use, July 386
 - selection, July 385-386
 - therapy, approaches to, July 384-390
- Antibiotics: causing anaphylaxis, Aug. 452
- Antibodies
 - in anaphylaxis, Aug. 443-444
 - autoantibodies in dermatomyositis/polymyositis, May 266
- Antibradycardia pacing, July 387
- Anticonvulsant(s)
 - action, proposed mechanisms of, Nov. 653
 - agents, Nov. 658-661
 - choice of, Nov. 651-655
 - by seizure type, Nov. 653
 - discontinuation, Nov. 661
 - experimental, Nov. 661
 - interactions, Nov. 657
 - parenteral, pharmacokinetics, Nov. 664

Anticonvulsant(s) (*cont.*)

pharmacokinetics, Nov. 659

Antihistamines: in anaphylaxis, Aug. 467

Antimicrobial systems: in neutrophils, Dec. 705

Antitachycardia pacing, July 388

Apexcardiography: in mitral valve prolapse, Sept. 510

Arachidonic acid metabolites: neutrophil stimulation initiating intracellular synthesis of, Dec. 697

ARDS (*see* Respiratory distress syndrome, adult)

Arrhythmia(s), July 377-432

during anaphylaxis, Aug. 461

automaticity and (*see* Automaticity)

bradyarrhythmias, July 414

cellular basis, July 377-381

defibrillator in, automatic implantable cardioverter, July 388-389

electrophysiology, intracardiac, July 382-383

esophageal studies in, July 383-384

exercise testing in, July 384

fulguration in, intracardiac, July 389

hyparrhythmia, Nov. 631

impulse conduction and, abnormal, July 379-381

in mitral valve prolapse, Sept. 519-520

monitoring, ambulatory, July 382

neural mechanisms, July 381

pacing in, July 386-388

reentry and, abnormal, July 379-381

signal averaging techniques in, July 384

sinus, July 414-415

clinical aspects, July 414-415

recognition, July 414

treatment, July 415

study methods, July 381-384

surgery in, July 389-390

tachyarrhythmia (*see* Tachyarrhythmias)

Arteries (*see* Coronary artery)

Arthritis

in erythema nodosum, Apr. 214

gonococcal infection and, disseminated, Apr. 212-213

in hepatitis B, Apr. 214

in Reiter's syndrome, Apr. 213-214

sexually transmitted diseases and, Apr. 212-215

in syphilis, Apr. 214

Articular manifestations: in myositis, May 277

Aspergillosis: invasive pulmonary, definitive diagnosis, Jan. 39

Aspiration syndromes, Jan. 25-27

Aspirin (*see* Pulmonary disease, aspirin-induced)

Athletes: elite female, osteoporosis in, Oct. 565-566

Atrial

fibrillation (*see* Fibrillation, atrial)

flutter (*see* Flutter, atrial)

pacemaker (*see* Pacemaker, wandering atrial)

tachycardia (*see* Tachycardia, atrial)

Atriopeptides: in shock, June 328

Atrioventricular (*see* AV)

Aura: in anaphylaxis, Aug. 457

Autoantibodies: in dermatomyositis/polymyositis, May 266

Autoimmunity: and dermatomyositis/polymyositis, May 261

Automaticity

abnormal, July 378-379

clinical implications, July 378-379

normal, July 378

clinical implications, July 378

triggered, July 379

clinical implications, July 379

Automatisms: in complex partial seizures, Nov. 625

AV

block (*see* Block, AV)

junctional tachycardia (*see*
Tachycardia, accelerated AV
junctional)
nodal reentry tachycardia (*see*
Tachycardia, AV nodal reen-
try)
reentry (*see* Reentry, AV, via con-
cealed accessory pathway)

B

Bacteria

pneumonia due to, Jan. 23-25
vaginosis due to (*see* Vaginosis,
bacterial)

Bactericidal activity: nonoxidative,
of neutrophils, Dec. 705-706

Benzodiazepines: in seizures, Nov.
661

Biopsy

bone, in osteopenia, Oct. 570-571
muscle, in dermatomyositis/poly-
myositis, May 249-252
initial, inflammatory and struc-
tural changes in, May 250

Blastomycosis, Jan. 34

Bleomycin (*see* Pulmonary disease,
bleomycin-induced)

Block

AV, July 420-424

AV, acute, July 423-424
clinical aspects, July 423
recognition, July 423
treatment, July 423-424

AV, chronic, July 420-423
clinical aspects, July 421
recognition, July 420-421
treatment, July 421, 423

AV conduction, July 420
intraventricular conduction,
acute, July 425-426
clinical aspects, July 425
recognition, July 425
treatment, July 425-426

intraventricular conduction,
chronic, July 424-425
clinical aspects, July 424-425
recognition, July 424
treatment, July 425

sinus exit, July 415
clinical aspects, July 415
recognition, July 415
treatment, July 415
trifascicular, July 422

Blood component transfusions: and
drug-induced pulmonary
disease, Feb. 83

Bohan and Peter

classification of dermatomyositis/
polymyositis, May 269
conclusions about dermatomyosi-
tis/polymyositis, 1975, May
248

Bone

biopsy in osteopenia, Oct. 570-
571
cortical, remodeling, Oct. 550-555
loss, age-related, pathophysiol-
ogy, Oct. 551-555
mass

changes with advancing age,
Oct. 549
serial measurements determin-
ing efficacy of osteoporosis
therapy, Oct. 577
mineral density serial measure-
ments determining efficacy
of osteoporosis therapy, Oct.
577

remodeling, cellular sequence of
events in, Oct. 553

trabecular, remodeling, Oct. 550-
555

Bradyarrhythmias, July 414

Bradycardia, sinus, July 414-415
clinical aspects, July 414-415
recognition, July 414
treatment, July 415

Brain damage: epileptic, Nov. 620

Bronchiolitis obliterans: drug-in-
duced, Feb. 79-80

Bronchospasm in anaphylaxis, Aug.
459

treatment, Aug. 467-468

Burrows: in sexually transmitted
scabies, Apr. 217-218

Busulfan (*see* Pulmonary disease,
busulfan-induced)

C

- Calcitonin in osteoporosis, Oct. 557-558
 as cause of, Oct. 557-558
 prophylactic, Oct. 586
 therapeutic, Oct. 585-588
- Calcium
 abnormalities in osteopenia, Oct. 569-570
 oral, in osteoporosis, prophylactic, Oct. 580
 oral, in osteoporosis, therapeutic, Oct. 583-584
 mode of action, Oct. 583
 rationale, Oct. 583
 specifics of regimen, Oct. 584
- Cancer (*see* Malignancy)
- Candida*: in granulocytopenia, Jan. 40
- Candidiasis, vaginal, Mar. 140-142
 contacts, Mar. 142
 diagnosis, Mar. 141
 epidemiology, Mar. 140-141
 physical examination, Mar. 141
 predisposing factors, Mar. 140-141
 symptoms, Mar. 141
 treatment, Mar. 141-142
- Carbamazepine
 pulmonary disease due to, Feb. 110
 in seizures, Nov. 658-659
- Carbon monoxide: diffusing capacity, for detection of drug-induced pulmonary disease, Feb. 84
- Cardiac (*see* Heart)
- Cardiogenic shock, June 338-339
- Cardiovascular collapse (*see* Anaphylaxis, cardiovascular collapse in)
- Cardioverter defibrillator: automatic implantable, in arrhythmias, July 388-389
- Carotid sinus (*see* Hypersensitive carotid sinus syndrome)
- Catamenial seizures, Nov. 655-656
- Catecholamines
 endogenous, biosynthetic pathway of, June 346
 selectivity for adrenergic receptors, June 324
 in shock, June 321-324
- Catheterization: cardiac, in mitral valve prolapse, Sept. 511
- Cell
 "epileptic," Nov. 617
 epithelial, in pneumonia, Jan. 14
 loss, hippocampal, in epilepsy, Nov. 621
 -mediated immunity in dermatomyositis/polymyositis, May 267
- Cellular
 basis
 of antiarrhythmic drug action, July 384-385
 of arrhythmias, July 377-381
 constituents of lung, and pulmonary toxic drugs, Feb. 74
 neurophysiology of epilepsy, Nov. 615-618
 sequence of events in bone remodeling, Oct. 553
- Central nervous system infections: and partial epilepsy, Nov. 637
- Cerebellar function: in seizures, Nov. 645
- Cerebrovascular disease: and partial epilepsy, Nov. 639
- Cervicitis
 chlamydial, Mar. 150-154
 contacts, Mar. 154
 diagnosis, Mar. 153-154
 epidemiology, Mar. 150, 152
 physical examination, Mar. 152-153
 risk factors, Mar. 150, 152
 symptoms, Mar. 152-153
 treatment, Mar. 151, 154
- gonococcal, Mar. 146-150
 contacts, Mar. 150
 diagnosis, Mar. 148-149
 epidemiology, Mar. 146-147
 physical examination, Mar. 147-148
 symptoms, Mar. 147-148
 treatment, Mar. 149-150, 151
 mucopurulent, Mar. 145-155

- Chancroid, Apr. 200-202
 contacts, Apr. 202
 diagnosis, Apr. 201
 epidemiology, Apr. 200
 microbiology, Apr. 200
 physical findings, Apr. 200-201
 symptoms, Apr. 200-201
 treatment, Apr. 201
- Chédiak-Higashi syndrome, Dec. 734-736
- Chemoattractants, Dec. 695
- Chemotaxis, neutrophil, Dec. 694-698
 disorders, Dec. 728-733
- Chest
 pain in mitral valve prolapse, Sept. 516-518
 wall
 rash on, in dermatomyositis, May 257
 syndrome in mitral valve prolapse, Sept. 516-517
 x-rays (see Radiography, chest)
- Children
 (See also Juvenile)
 dermatomyositis in, and retinopathy, May, 280
 epilepsy in
 absence, Nov. 634-635
 with centrottemporal spikes, Nov. 635
 with occipital paroxysms, Nov. 635
 infantile spasm, clinical presentation, Nov. 631
 newborn, seizures in, Nov. 632-633
- Chlamydia trachomatis*
 cervicitis (see Cervicitis, chlamydial)
 urethritis
 (See also Urethritis, chlamydial)
 negative nongonococcal, Mar. 154-155
- Chlorambucil (see Pulmonary disease, chlorambucil-induced)
- Chymopapain: causing anaphylaxis, Aug. 453
- Clean living: and osteoporosis, Oct. 578
- Click
 diastolic, early, in mitral valve prolapse, Sept. 503
 midsystolic, in mitral valve prolapse, Sept. 501, 503
 nonejection, causes, Sept. 505
 systolic, late, in mitral valve prolapse, Sept. 502
- Coffee ingestion: and osteoporosis, Oct. 576
- Collagen-vascular diseases: and overlap myositis, May 275
- Colloid solutions: causing anaphylaxis, Aug. 454
- Communication: and anaphylaxis, Aug. 471-472
- Complement
 5a, Dec. 695
 system in anaphylaxis, Aug. 445
- Computed tomography (see Tomography, computed)
- Conduction
 blocks
 atrioventricular, July 420
 intraventricular (see Block, intraventricular conduction)
 impulse, abnormal, July 379-381
 clinical implications, July 380-381
- Connective tissue disorders: and myositis, May 273-277
- Contraceptives: oral, and seizures, Nov. 656
- Contrast media: causing anaphylaxis, Aug. 452-453
- Convulsions
 febrile, Nov. 635
 as cause of epilepsy, Nov. 638-639
 primary generalized, Nov. 630
- Coronary artery
 disease and mitral valve prolapse, Sept. 517-518
 spasm in mitral valve prolapse, Sept. 517
- Cortical bone: remodeling of, Oct. 550-555
- Cortical functions: higher, and seizures, Nov. 643-644

Cranial nerve examination: in seizures, Nov. 644

Creatine kinase elevations: conditions associated with, May 253

CT (*see* Tomography, computed)

Cushing's disease: and osteoporosis, Oct. 560-561

Cutaneous (*see* Skin)

Cuticular overgrowth: in dermatomyositis, May 259

Cyclophosphamide (*see* Pulmonary disease, cyclophosphamide-induced)

Cytosine arabinoside: inducing pulmonary disease, Feb. 98

Cytotoxic agents

in myositis, malignancies after, May 285

pulmonary disease due to, Feb. 98

D

Death: sudden, in mitral valve prolapse, Sept. 519-520

Defibrillator: automatic implantable cardioverter, in arrhythmias, July 388-389

Deformity: in osteoporosis, Oct. 567

Depolarization

shift, paroxysmal, Nov. 616

ionic conductances during, Nov. 616

surface, extracellular unit, and intracellular recordings during, Nov. 617

ventricular premature, July 403-407

clinical aspects, July 405-406

recognition, July 403-405

treatment, July 406-407

Dermatomyositis

childhood, retinopathy in, May 280

cutaneous lesions in, May 254-259

cuticular overgrowth in, May 259

Gotttron's papules in, May 255

/polymyositis (*see below*)

rash in

on chest wall, May 257

on hand, May 256

telangiectasias in, periungual, May 258

Dermatomyositis/polymyositis, May 247-305

adult, May 269-272

articular manifestations, May 277

autoantibodies in, May 266

autoimmunity and, May 261

biopsy in, muscle, May 249-252

initial, inflammatory and structural changes in, May 250

Bohan and Peter's 1975 conclusions about, May 248

cardiac disease in, May 279

classification, May 268-269

Bohan and Peter, May 269

Walton and Adams, May 268

clinical features, May 269-280

conditions associated with, May 260

diagnosis, May 247-259

diagnostic criteria, May 247-259

disease production in, mechanisms, May 267-268

drug-induced, May 263-264

electromyogram in, May 252-253

enzymes in, muscle, May 253-254

esophageal abnormalities in, May 277-278

etiologic factors, May 259-267

immunity in, cell-mediated, May 267

immunogenetics, May 265-266

immunologic studies in, May 265-267

infections and, May 261-262

juvenile, May 272-273

malignancy and, May 261, 281-286

muscle weakness in, May 249

nephropathy and, May 280

pathogenesis, May 259-267

pregnancy and, May 279-280

pulmonary disease in, May 278-279

serologic studies in, May 266-267

signs, May 274

symptoms, May 274
 therapy, May 289-293
 vaccinations and, May 262-263
 Desensitization: and anaphylaxis,
 Aug. 474
 Diabetes mellitus: and osteoporosis,
 Oct. 563-564
 Diastolic click: early, in mitral valve
 prolapse, Sept. 503
 Diet
 as cause of osteoporosis, Oct.
 555-556
 osteoporosis and, Oct. 575
 Diffusing capacity: carbon monox-
 ide, for detection of drug-in-
 duced pulmonary disease,
 Feb. 84
 1,25-Dihydroxyvitamin D: in osteo-
 porosis, Oct. 587-588
 Dilantin: inducing pulmonary dis-
 ease, Feb. 110
 Diplococci: gram-negative, Jan. 14
 Donovanosis (*see* Granuloma in-
 guinale)
 Driving: and epilepsy, Nov. 665
 Drug(s)
 anaphylaxis due to (*see* Anaphy-
 laxis, drugs causing)
 in anaphylaxis, Aug. 465-467
 experimental, Aug. 468-469
 antiarrhythmic (*see* Antiar-
 rhythmic, agents)
 -induced
 bronchiolitis obliterans, Feb.
 79-80
 myositis, May 263-264
 pneumonitis/fibrosis, Feb. 76-
 77
 pneumonitis, hypersensitivity,
 Feb. 77-79
 pulmonary disease (*see* Pulmo-
 nary disease, drug-induced)
 pulmonary edema, noncardio-
 genic, Feb. 79
 renal syndrome, pulmonary,
 Feb. 80
 interactions, and seizures, Nov.
 656, 657
 intoxication causing seizures,
 Nov. 641

noncytotoxic, causing pulmonary
 disease, Feb. 111
 pulmonary toxic, and cellular
 constituents of lung, Feb. 74
 therapy, and drug-induced pul-
 monary disease, Feb. 83

E

ECG (*see* Electrocardiography)
 Echocardiography: in mitral valve
 prolapse, Sept. 507-510
 EEG (*see* Electroencephalography)
 Edema
 angioneurotic, in anaphylaxis,
 Aug. 458-459
 generalized, in anaphylaxis, Aug.
 462
 pulmonary, noncardiogenic
 in anaphylaxis, Aug. 462
 drug-induced, Feb. 79
 Eicosanoids: in shock, June 332-333
 Electrocardiography
 in atrial fibrillation, July 394
 changes in cardiovascular col-
 lapse due to anaphylaxis,
 Aug. 461
 of hypersensitive carotid sinus
 syndrome, July 419
 in mitral valve prolapse, Sept.
 506-507
 of sinus arrest, July 416
 of tachycardia
 atrial, July 392
 ventricular, July 408
 of torsade de pointes, July 413
 of trifascicular block, July 422
 Electrodes (*see* Electroencephalog-
 raphy in seizures, electrodes
 for)
 Electroencephalography in seizures,
 Nov. 646-649
 electrodes for
 extra, Nov. 648
 intracranial, Nov. 648
 monitoring and
 ambulatory, Nov. 648-649
 video, Nov. 648
 routine, Nov. 646-647
 sleep deprivation and, Nov. 647

- Electrolytes: in shock, June 328-330
- Electromyogram: in dermatomyositis/polymyositis, May 252-253
- Electrophysiology: intracardiac, in arrhythmias, July 382-383
- Employment: and epilepsy, Nov. 665
- Endocarditis: infective, in mitral valve prolapse, Sept. 518-519
- Endocrine system: in osteoporosis, Oct. 557
- Endorphins: in shock, June 333-334
- Enkephalins: in shock, June 333-334
- Environmental influences
in osteoporosis, Oct. 556
in shock, June 334
- Enzymes: muscle, in dermatomyositis/polymyositis, May 253-254
- Epididymitis, Mar. 156-157
diagnosis, Mar. 156
physical examination, Mar. 156
symptoms, Mar. 156
treatment, Mar. 156-157
- Epilepsia partialis continua, Nov. 634
- Epilepsy, Nov. 613-679
absence
childhood, Nov. 634-635
juvenile, Nov. 635
alcohol and, Nov. 663, 665
childhood
with centrotemporal spikes, Nov. 635
with occipital paroxysms, Nov. 635
classification, international, Nov. 624
control, adequate, Nov. 665-666
driving and, Nov. 665
employment and, Nov. 665
febrile convulsions as cause of, Nov. 638-639
generalized, Nov. 634-635
hippocampal cell loss in, Nov. 621
history, Nov. 614-615
management, life-style issues in, Nov. 663-665
medical intractability, Nov. 666
myoclonic, juvenile, Nov. 635
neurobiology of, Nov. 618-622
neurophysiology, cellular and synaptic, Nov. 615-618
nosology of, Nov. 622-626
partial, Nov. 635
cerebrovascular disease and, Nov. 639
etiologic factors in, Nov. 636-639
head trauma and, Nov. 637-638
hereditary influences in, Nov. 636
immunologic disorders and, Nov. 639
infections and, central nervous system, Nov. 637
neoplasms and, Nov. 638
neurosurgery and, Nov. 637-638
perinatal insults and, Nov. 636-637
physiology, Nov. 615-622
systemic, Nov. 622
psychopathology and, Nov. 662
sexuality and, Nov. 665
sleep deprivation and, Nov. 663
social isolation and, Nov. 665
surgery in, Nov. 666-668
outcome, Nov. 668
preoperative evaluation, Nov. 666-667
risks, Nov. 668
types of procedures, Nov. 667-668
- Epileptic
"aggregate," Nov. 617
brain damage, Nov. 620
"cell," Nov. 617
seizures, international classification, Nov. 623
syndromes, Nov. 634-636
classification of, international, Nov. 624
genetically determined, Nov. 634-636
- Epileptiform EEG abnormalities, Nov. 647
- Epileptogenesis: secondary, Nov. 620
- Epithelial cells: in pneumonia, Jan. 14

Erythema
 nodosum, sexually transmitted,
 and arthritis, Apr. 214
 multiforme, rash in, Apr. 216

Esophagus
 abnormalities in dermatomyosi-
 tis/polymyositis, May 277-278
 dysfunction in mitral valve pro-
 lapse, Sept. 518
 studies in arrhythmias, July 383-
 384

Estrogen in osteoporosis
 prophylactic, Oct. 579-580
 therapeutic, Oct. 581-583
 contraindications, Oct. 583
 mode of action, Oct. 582
 rationale, Oct. 581-582
 side effects, Oct. 582-583
 specifics of regimen, Oct. 582

Ethanol (see Alcohol)

Ethnic influences: in osteoporosis,
 Oct. 556

Ethosuximide: in seizures, Nov. 660

Examination
 neurologic, in seizures, Nov. 643-
 646
 physical
 in AIDS, Apr. 225-226
 in candidiasis, vaginal, Mar.
 141
 in cervicitis, chlamydial, Mar.
 152-153
 in cervicitis, gonococcal, Mar.
 147-148
 in epididymitis, Mar. 156
 in granuloma inguinale, Apr.
 203-204
 in lymphogranuloma vene-
 reum, Apr. 202-203
 in molluscum contagiosum,
 Apr. 204-205
 in seizures, Nov. 643
 in syphilis, Apr. 198
 in trichomoniasis, Mar. 138
 in urethritis, chlamydial, Mar.
 152-153
 in urethritis, gonococcal, Mar.
 147-148
 in vaginosis, bacterial, Mar. 143
 in warts, genital, Apr. 205-206

Excoriations: in sexually transmit-
 ted scabies, Apr. 217-218

Exercise
 -induced anaphylaxis, Aug. 455
 moderate weight-bearing, and os-
 teoporosis, Oct. 578-579
 testing in arrhythmias, July 384

F

Febrile convulsions, Nov. 635
 as cause of epilepsy, Nov. 638-639

Fibrillation
 atrial, July 393-397
 clinical aspects, July 395-396
 ECG, July 394
 recognition, July 393-395
 treatment, July 396-397
 ventricular, sustained, July 407-
 411
 clinical aspects, July 409
 recognition, July 407-409
 treatment, July 409-411

Fibrosis/pneumonitis: drug-in-
 duced, Feb. 76-77

Fitz-Hugh-Curtis syndrome, Apr.
 210-211

Fluoride in osteoporosis
 prophylactic, Oct. 580
 therapeutic, Oct. 584-585

Flutter, atrial, July 393-397
 clinical aspects, July 395-396
 recognition, July 393-395
 treatment, July 396-397

Foods: causing anaphylaxis, Aug.
 455

Fracture
 in osteoporosis, Oct. 567
 rate in determining efficacy of os-
 teoporosis therapy, Oct. 577

Fulguration: intracardiac, in ar-
 rhythmias, July 389

Fungal pneumonia, Jan. 31-34

G

Gallium scanning: in drug-induced
 pulmonary disease, Feb. 85

Gastrointestinal symptoms: in ana-
 phylaxis, Aug. 462

Genetics: and mitral valve prolapse,
Sept. 493-498

Genital

herpes (see Herpes, genital)

ulcer, Apr. 193-209

warts (see Warts, genital)

Glucagon

heart rate response to, June 327

in shock, June 326-327

Glucose-6-phosphate dehydroge-
nase deficiency, Dec. 742-743

Glutathione

reductase deficiency, Dec. 743-
745

synthetase deficiency, Dec. 743-
745

Glycoprotein, CD11/CD18, Dec. 715
deficiency

clinical features, Dec. 718

leukocyte function abnormali-
ties in, Dec. 717

Gold salts (see Pulmonary disease,
gold salt-induced)

Gonadal hormones: in osteoporosis,
Oct. 556-557

Gonococcal

cervicitis (see Cervicitis, gonococ-
cal)

infection, disseminated, arthritis
in, Apr. 212-213

urethritis (see Urethritis, gono-
coccal)

Gotttron's papules, May 255

Granule (see Neutrophil, granule)

Granulocytopenia: *Candida* in, Jan. 40

Granuloma inguinale, Apr. 203-204

diagnosis, Apr. 204

epidemiology, Apr. 203

microbiology, Apr. 203

physical examination, Apr. 203-
204

symptoms, Apr. 203-204

treatment, Apr. 204

Granulomatous disease, chronic,
Dec. 738-742

synopsis of, Dec. 739

Guanine

nucleotides, coupling to neutro-
phil receptors, Dec. 698-703
regulatory proteins, Dec. 699

H

Hand: rash on, in dermatomyositis,
May 256

Head trauma: and partial epilepsy,
Nov. 637-638

Heart

arrhythmia (see Arrhythmia)

cardiovascular collapse (see Ana-
phylaxis, cardiovascular col-
lapse in)

catheterization in mitral valve
prolapse, Sept. 511

disease

in dermatomyositis/polymyosi-
tis, May 279

ischemic, arrhythmias during
anaphylaxis in, Aug. 461

filling pressures in cardiovascular
collapse due to anaphylaxis,
Aug. 461

intracardiac (see Intracardiac)

pacing therapy in arrhythmias,
July 386-387

rate response to glucagon, June
327

Hemophilus influenzae pneumonia,
Jan. 22

Heparin osteoporosis, Oct. 562

Hepatitis

B, sexually transmitted

arthritis in, Apr. 214

urticaria in, Apr. 217

perihepatitis, Apr. 210-211

syndrome, sexually transmitted
acute viral, Apr. 211-212

Hereditary influences: in partial epi-
lepsy, Nov. 636

Heroin (see Pulmonary disease, her-
oin-induced)

Herpes

genital, Apr. 194-197

contacts, Apr. 197

diagnosis, Apr. 195-196

epidemiology, Apr. 194

symptoms, Apr. 194-195

treatment, Apr. 196-197

simplex, and partial epilepsy,
Nov. 637

Hippocampal cell loss: in epilepsy, Nov. 621
 Histamine: and anaphylaxis, Aug. 449-451
 Homosexual male: *Pneumocystis carinii* pneumonia in, Jan. 42
 Hormones
 in osteoporosis (see Osteoporosis, hormones in)
 in shock (see Shock, hormones in)
 Hydrochlorothiazide: inducing pulmonary disease, Feb. 109-110
 Hymenoptera: causing anaphylaxis, Aug. 455
 Hyperparathyroidism: causing osteopenia, Oct. 590-591
 Hypersensitive carotid sinus syndrome, July 418-420
 clinical aspects, July 418
 ECG, July 419
 recognition, July 418
 treatment, July 418, 419
 Hypersensitivity pneumonitis: drug-induced, Feb. 77-79
 Hypnosedative withdrawal: causing seizures, Nov. 640-641
 Hypothalamic-pituitary-adrenal axis: in shock, June 330-331
 Hypovolemic shock, June 335
 Hypsarrhythmia, Nov. 631

I

Immobilization osteoporosis, Oct. 561-562
 Immunity
 autoimmunity, and dermatomyositis/polymyositis, May 261
 cell-mediated, in dermatomyositis/polymyositis, May 267
 Immunocompromised patients: non-infectious causes of pneumonia in, Jan. 38
 Immunodeficiency
 syndrome, acquired (see AIDS) virus, human, Apr. 223-227
 Immunogenetics: of dermatomyositis/polymyositis, May 265-266

Immunoglobulins in anaphylaxis (see Anaphylaxis, immunoglobulin in)
 Immunologic
 disorders, and partial epilepsy, Nov. 639
 studies in dermatomyositis/polymyositis, May 265-267
 Immunosuppressive agents: in myositis, malignancies after, May 285
 Impulse conduction, abnormal, July 379-381
 clinical implications, July 380-381
 Inactivity: and osteoporosis, Oct. 576
 Infantile spasms: clinical presentation, Nov. 631
 Infections
 central nervous system, and partial epilepsy, Nov. 637
 dermatomyositis/polymyositis and, May 261-262
 recurrent, patient with algorithm for workup, Dec. 744
 diagnostic evaluation, Dec. 745
 Infective endocarditis: in mitral valve prolapse, Sept. 518-519
 Inguinal lymphadenopathy, Apr. 193-209
 Inheritance: and mitral valve prolapse, Sept. 493-498
 Injury (see Trauma)
 Inotropic agents in shock, June 347-348
 dosages, June 351
 Interictal spike, Nov. 618
 Intoxication
 drug, causing seizures, Nov. 641
 ethanol, causing seizures, Nov. 640
 Intracardiac
 electrophysiologic studies in arrhythmias, July 382-383
 fulguration in arrhythmias, July 389
 Intracranial electrodes: for EEGs in seizures, Nov. 648

Intraventricular conduction block
 (see Block, intraventricular
 conduction)
 Ionic conductances: during parox-
 ysmal depolarization shift,
 Nov. 616
 Ischemic heart disease: arrhythmias
 during anaphylaxis in, Aug.
 461

J

Juvenile
 (See also Children)
 absence epilepsy, Nov. 635
 dermatomyositis/polymyositis,
 May 272-273
 myoclonic epilepsy, Nov. 635
 osteoporosis, Oct. 560

K

Kaposi's sarcoma: in AIDS, Apr. 218
 Kidney (see Renal)
 Kinetics: neutrophil, Dec. 693-694

L

Laboratory data: in sexually trans-
 mitted diseases, Apr. 232-233
 Lactation: and osteoporosis, Oct.
 566
 Leanness: and osteoporosis, Oct.
 576
 Legionnaire's disease, Jan. 20-21
 Lennox-Gastaut syndrome, Nov. 636
 Leukocyte
 adherence deficiency, congenital,
 Dec. 714-719
 function abnormalities in CD11/
 CD18 glycoprotein defi-
 ciency, Dec. 717
 Lice (see Pediculosis)
 Life-style issues: in management of
 epilepsy, Nov. 663-665
 Liver disease: chronic, and osteopo-
 rosis, Oct. 561
 Living: clean, and osteoporosis, Oct.
 578
 Lung
 (See also Pulmonary)

cellular constituents, and pulmo-
 nary toxic drugs, Feb. 74
 volumes, and drug-induced pul-
 monary disease, Feb. 84
 Lymphadenopathy: inguinal, Apr.
 193-209
 Lymphogranuloma venereum, Apr.
 202-203
 contacts, Apr. 203
 diagnosis, Apr. 203
 epidemiology, Apr. 202
 microbiology, Apr. 202
 physical examination, Apr. 202-
 203
 symptoms, Apr. 202-203
 treatment, Apr. 203

M

Malabsorption: and osteoporosis,
 Oct. 564
 Malignancy
 dermatomyositis/polymyositis
 and, May 261, 281-286
 osteopenia and, Oct. 569
 Marathon runners: osteoporosis in,
 Oct. 565-566
 Mediators
 in anaphylaxis, Aug. 444-445, 446
 soluble, in drug-induced pulmo-
 nary disease, Feb. 85
 Melphalan (see Pulmonary disease,
 melphalan-induced)
 Menopause: early, and osteopo-
 rosis, Oct. 575
 Metabolic disorders: causing sei-
 zures, Nov. 641-642
 Methadone (see Pulmonary disease,
 methadone-induced)
 Methotrexate (see Pulmonary dis-
 ease, methotrexate-induced)
 Microbiology
 of chancroid, Apr. 200
 of granuloma inguinale, Apr. 203
 of lymphogranuloma venereum,
 Apr. 202
 of molluscum contagiosum, Apr.
 204
 of pediculosis, Apr. 207
 of syphilis, Apr. 197-198

- of warts, genital, Apr. 205
- Midsystolic click: in mitral valve prolapse, Oct. 501, 503
- Mitomycin-induced pulmonary disease, Feb. 93-94
 - clinical features, Feb. 93-94
- Mitral valve
 - floppy, Sept. 494
 - prolapse, Sept. 491-534
 - angiography in, Sept. 511-516
 - apexcardiography in, Sept. 510
 - arrhythmias in, Sept. 519-520
 - cardiac catheterization in, Sept. 511
 - chest pain in, Sept. 516-518
 - chest wall syndrome in, Sept. 516-517
 - click in, diastolic, early, Sept. 503
 - click in, midsystolic, Sept. 501, 503
 - click in, systolic, late, Sept. 502
 - clinical features, Sept. 500-506
 - complications, Sept. 516-520
 - conditions associated with, Sept. 496-497, 498-499
 - coronary artery disease and, Sept. 517-518
 - coronary artery spasm in, Sept. 517
 - definition, Sept. 491
 - doughnut-shaped appearance, Sept. 512
 - echocardiography in, Sept. 507-510
 - electrocardiography in, Sept. 506-507
 - endocarditis in, infective, Sept. 518-519
 - esophageal dysfunction in, Sept. 518
 - genetics and, Sept. 493-498
 - historical background, Sept. 491
 - inheritance and, Sept. 493-498
 - mitral regurgitation in, Sept. 518
 - murmur in, late systolic, Sept. 501-502
 - myocardial supply/demand imbalance in, Sept. 517
 - papillary muscle in, Sept. 517
 - pathology, Sept. 493
 - pathophysiology, Sept. 499
 - phonocardiography in, Sept. 510
 - prevalence, Sept. 491-493
 - psychosomatic complaint in, Sept. 518
 - scintigraphy in, radionuclide, Sept. 511
 - sudden death in, Sept. 519-520
 - systolic time intervals in, Sept. 510
 - thromboembolism in, Sept. 519
 - treatment, Sept. 520
 - vectorcardiography in, Sept. 506-507
 - ventricular dysfunction in, left, Sept. 517
 - view of, Sept. 495
 - pseudoprolapse, Sept. 513
 - regurgitation in mitral valve prolapse, Sept. 518
 - Molluscum contagiosum, Apr. 204-205
 - diagnosis, Apr. 205
 - epidemiology, Apr. 204
 - microbiology, Apr. 204
 - physical examination, Apr. 204-205
 - symptoms, Apr. 204-205
 - treatment, Apr. 205
 - Monitoring
 - ambulatory, of arrhythmias, July 382
 - EEG (*see* Electroencephalography in seizures, monitoring and)
 - Mononucleosis syndrome: and sexually transmitted disease, Apr. 215
 - Motor examination: in seizures, Nov. 644
 - Murmur, late systolic
 - differential diagnosis, Sept. 504
 - in mitral valve prolapse, Sept. 501-502
 - Muscle
 - biopsy in dermatomyositis/poly-myositis, May 249-252

Muscle (*cont.*)

- initial, inflammatory and structural changes in, May 250
- enzymes in dermatomyositis/polymyositis, May 253-254
- papillary, in mitral valve prolapse, Sept. 517
- weakness in dermatomyositis/polymyositis, May 249
- Mycoplasma pneumonia, Jan. 29
- Myeloma: causing osteopenia, Oct. 591-592
- Myeloperoxidase deficiency, Dec. 743
- Myocardial supply/demand imbalance: in mitral valve prolapse, Sept. 517
- Myositis
 - (See also Dermatomyositis and Dermatomyositis/polymyositis)
 - conditions associated with, May 260
 - connective tissue disorders and, May 273-277
 - overlap
 - collagen-vascular diseases and, May 275
 - symptoms and signs, May 274
 - patient, evaluation of, May 286-289

N

- Neisseria gonorrhoeae* (see Cervicitis, gonococcal; Urethritis, gonococcal)
- Neonatal seizures: clinical presentation, Nov. 632-633
- Neoplasms (see Tumors)
- Nephropathy: and myositis, May 280
- Nerves: cranial, examination, in seizures, Nov. 644
- Nervous system infections: central, and partial epilepsy, Nov. 637
- Neural mechanisms: of arrhythmias, July 381
- Neurobiology: of epilepsy, Nov. 618-622
- Neurologic examination: in seizures, Nov. 643-646
- Neurophysiology: of epilepsy, Nov. 615-618
- Neurosurgery: and partial epilepsy, Nov. 637-638
- Neutron activation analysis: in osteopenia, Oct. 573-574
- Neutropenia, Dec. 713-714
 - conditions characterized by and associated with, Dec. 715
- Neutrophil
 - adherence disorders, Dec. 714-719
 - acquired, Dec. 720
 - clinical manifestations, Dec. 718-719
 - therapy, Dec. 719
 - antimicrobial systems, Dec. 705
 - bactericidal activity, nonoxidative, Dec. 705-706
 - chemotaxis, Dec. 694-698
 - disorders, Dec. 728-733
 - degranulation disorders, Dec. 734-736
 - function disorders, Dec. 693-755
 - granule
 - deficiency, specific, Dec. 737-738
 - function, Dec. 706-707
 - ingestion disorders, Dec. 734
 - kinetics, Dec. 693-694
 - motile responses, Dec. 704-705
 - motility disorders, Dec. 728-733
 - oxidant removal disorders, Dec. 743-745
 - oxidative metabolism of, Dec. 707-713
 - oxidative microbicidal activity disorders, Dec. 738-743
 - pool, total body, Dec. 694
 - receptors, coupling of guanine nucleotides to, Dec. 698-703
 - responses, G proteins as integrators of, Dec. 702

stimulation, intracellular synthesis of arachidonic acid metabolites after, Dec. 697
 Nitrofurantoin (*see* Pulmonary disease, nitrofurantoin-induced)
 Nitrosurea (*see* Pulmonary disease, nitrosurea-induced)
 Nosocomial pneumonia, Jan. 34-40
 Nosology: of seizures and epilepsy, Nov. 622-626
 Nucleotides: guanine, coupling to neutrophil receptors, Dec. 698-703

O

Oposonization: clinical disorders of, Dec. 733
 Oral contraceptives: and seizures, Nov. 656
 Oropharyngeal disease: sexually transmitted, Apr. 219-220
 Osmotic reactions: causing anaphylaxis, Aug. 454
 Osteitis fibrosa cystica: differentiated from osteopenia, Oct. 569
 Osteogenesis imperfecta: and osteoporosis, Oct. 564
 Osteomalacia
 causes, Oct. 589
 differentiated from osteopenia, Oct. 568-569
 osteopenia due to, Oct. 588-590
 Osteopenia, Oct. 547-600
 bone biopsy in, Oct. 570-571
 calcium abnormalities in, Oct. 569-570
 causes, Oct. 588-592
 diagnosis, differential, Oct. 567-569
 hyperparathyroidism causing, Oct. 590-591
 laboratory evaluation in, Oct. 569-574
 malignant disease and, Oct. 569
 myeloma causing, Oct. 591-592
 neoplastic disorders causing, Oct. 591-592

neutron activation analysis in, Oct. 573-574
 osteomalacia causing, Oct. 588-590
 phosphorus abnormalities in, Oct. 569-570
 photon absorptiometry in (*see* Photon absorptiometry)
 radiogrammetry in, Oct. 571
 terminology, Oct. 547-548
 thyrotoxicosis causing, Oct. 591
 tomography in, computerized, Oct. 573
 Osteoporosis, Oct. 548-558
 aggravating factors, Oct. 555-558
 nonhormonal, Oct. 555-556
 alcohol and, Oct. 576
 alcoholism and, Oct. 562-563
 in athletes, elite female, Oct. 565-566
 calcitonin in (*see* Calcitonin in osteoporosis)
 calcium in (*see* Calcium, oral, in osteoporosis)
 classification, Oct. 558-566
 clean living and, Oct. 578
 clinical features, Oct. 566-567
 coffee ingestion and, Oct. 576
 Cushing's syndrome and, Oct. 560-561
 deformity in, Oct. 567
 diabetes and, Oct. 563-564
 diet and, Oct. 575
 diet as cause of, Oct. 555-556
 1,25-dihydroxyvitamin D in, Oct. 587-588
 endocrine system in, Oct. 557
 environmental influences, Oct. 556
 estrogen in (*see* Estrogen in osteoporosis)
 ethnic influences, Oct. 556
 exercise and, moderate weight-bearing, Oct. 578-579
 female at risk, Oct. 575
 fluoride in (*see* Fluoride in osteoporosis)
 fracture in, Oct. 567
 heparin, Oct. 562

Osteoporosis (cont.)

- hormones in, Oct. 556-558
 - gonadal, Oct. 556-557
 - local regulatory, Oct. 558
 - parathyroid, Oct. 557
 - parathyroid, therapeutic, Oct. 587-588
- idiopathic, Oct. 559-560
- immobilization, Oct. 561-562
- inactivity and, Oct. 576
- involutional, Oct. 559
- juvenile, Oct. 560
- lactation and, Oct. 566
- leanness and, Oct. 576
- liver disease and, chronic, Oct. 561
- malabsorption and, Oct. 564
- in marathon runners, Oct. 565-566
- menopause and, early, Oct. 575
- osteitis fibrosa cystica differentiated from, Oct. 569
- osteogenesis imperfecta and, Oct. 564
- osteomalacia differentiated from, Oct. 568-569
- pain in, Oct. 566-567
- pathophysiology, Oct. 551-555
- physiologic stresses and illnesses and, Oct. 556
- postmenopausal, Oct. 559
- of pregnancy, Oct. 566
- primary, Oct. 559-560
- race and, Oct. 575
- risk factors, Oct. 574-577
- secondary, Oct. 560-566
 - diseases associated with, Oct. 576-577
- senile, Oct. 559
- smoking and, Oct. 575
- treatment, Oct. 578-588
 - ADFR approach, Oct. 587
 - in established disease, Oct. 580-588
 - methods of determining efficacy of, Oct. 577-578
 - preventative or prophylactic, Oct. 578-580
- Turner's syndrome and, Oct. 561
- vitamin D in, Oct. 557

- Oxidative metabolism: of neutrophils, Dec. 707-713
- Oxygen therapy: and drug-induced pulmonary disease, Feb. 82

P

- Pacemaker, wandering atrial, July 414-415
 - clinical aspects, July 414-415
 - recognition, July 414
 - treatment, July 415
- Pacing
 - antibradycardia, July 387
 - antitachycardia, July 388
 - in arrhythmias, July 386-388
- Pain
 - chest, in mitral valve prolapse, Sept. 516-518
 - in determining efficacy of osteoporosis therapy, Oct. 578
 - in osteoporosis, Oct. 566-567
- Papillary muscle: in mitral valve prolapse, Sept. 517
- Papules: Gottron's, May 255
- Parathyroid hormone in osteoporosis, Oct. 557
 - therapeutic, Oct. 587-588
- Paroxysmal depolarization shift (*see* Depolarization, shift, paroxysmal)
- Pediculosis, Apr. 207
 - diagnosis, Apr. 207
 - epidemiology, Apr. 207
 - microbiology, Apr. 207
 - symptoms, Apr. 207
 - treatment, Apr. 207
- Penicillamine-induced pulmonary disease, Feb. 108-109
 - clinical features, Feb. 108-109
- Perihepatitis, Apr. 210-211
- Perinatal insults: and partial epilepsies, Nov. 636-637
- Periungual telangiectasias: in dermatomyositis, May 258
- Pharmacokinetics of anticonvulsants, Nov. 659
 - parenteral, Nov. 664
- Pharmacotherapy (*See also* Drugs)

- of shock (see Shock, pharmacotherapy of)
- Phenobarbital: in seizures, Nov. 660
- Phenytoin: in seizures, Nov. 659-660
- Phonocardiography: in mitral valve prolapse, Sept. 510
- Phosphorus abnormalities: in osteopenia, Oct. 569-570
- Photon absorptiometry in osteopenia
dual beam, Oct. 572-573
single beam, Oct. 571-572
- Physical
examination (see Examination, physical)
inactivity, and osteoporosis, Oct. 576
stimuli causing anaphylaxis, Aug. 455-456
- Physiologic stresses and illness: and osteoporosis, Oct. 556
- Pituitary-hypothalamic-adrenal axis: in shock, June 330-331
- Pneumococcal pneumonia, Jan. 14, 17-20
- Pneumocystis carinii* pneumonia: in homosexual male, Jan. 42
- Pneumonia, Jan. 11-59
aspiration, Jan. 25-27
bacteria causing, Jan. 23-25
causes, Jan. 12
community-acquired, Jan. 17-34
diagnostic techniques
invasive, Jan. 15-17
noninvasive, Jan. 13-15
etiologies in AIDS, Jan. 42
fungal, Jan. 31-34
Hemophilus influenzae, Jan. 22
in immunocompromised patients, non-infectious causes, Jan. 38
mycoplasma, Jan. 29
nosocomial, Jan. 34-40
pneumococcal, Jan. 14, 17-20
Pneumocystis carinii, in homosexual male, Jan. 42
staphylococcal, Jan. 22-23
Streptococcus causing
pneumoniae, Jan. 17-20
pyogenes, Jan. 20
viral, Jan. 30-31
- Pneumonitis
/fibrosis, drug-induced, Feb. 76-77
hypersensitivity, drug-induced, Feb. 77-79
- Polymyositis (see Dermatomyositis/polymyositis)
- Postmenopausal osteoporosis, Oct. 559
- Preexcitation syndromes, July 400-403
clinical aspects, July 401-402
recognition, July 400-401
treatment, July 402-403
- Pregnancy
myositis and, May 279-280
osteoporosis of, Oct. 566
seizures and, Nov. 655
sexually transmitted diseases and, Apr. 231
- Preservatives: causing anaphylaxis, Aug. 454
- Pressor responsiveness: in shock, June 325-326
- Primidone: in seizures, Nov. 660
- Propoxyphene (see Pulmonary disease, propoxyphene-induced)
- Prostatitis, Mar. 157
- Protamine: causing anaphylaxis, Aug. 453-454
- Proteins
G
adenylate cyclase regulation by, mechanism of, Dec. 700
as integrators of neutrophil responses, Dec. 702
guanine regulatory, Dec. 699
- Psychopathology: and epilepsy, Nov. 662
- Psychosomatic complaint: in mitral valve prolapse, Sept. 518
- Pulmonary
(See also Lung)
aspergillosis, invasive, definitive diagnosis, Jan. 39
complications of AIDS, Jan. 41-43
disease (see below)
edema (see Edema, pulmonary)

Pulmonary (cont.)

renal syndrome, drug-induced,
Feb. 80

toxic drugs, and cellular constituents of lung, Feb. 74

Pulmonary disease

amiodarone-induced, Feb. 98-101

clinical features, Feb. 100-101

mechanisms, Feb. 99-100

aspirin-induced, Feb. 104-105

clinical features, Feb. 105

mechanisms, Feb. 104-105

bleomycin-induced, Feb. 85-89

clinical features, Feb. 87-89

mechanisms, Feb. 85-87

mechanisms, direct, Feb. 85-86

mechanisms, indirect, Feb. 87

busulfan-induced, Feb. 94-97

clinical features, Feb. 96-97

mechanisms, Feb. 95-96

carbamazepine-induced, Feb. 110

chlorthalidone-induced, Feb. 94-97

clinical features, Feb. 96-97

mechanisms, Feb. 95-96

cyclophosphamide-induced, Feb.

94-97

clinical features, Feb. 96-97

mechanisms, Feb. 95-96

cytosine arabinoside-induced,

Feb. 98

cytotoxic agents inducing, Feb. 98

in dermatomyositis/polymyositis,

May 278-279

dilantin-induced, Feb. 110

drug-induced, Feb. 71-120

administration and, route and

frequency of, Feb. 82

age and, Feb. 83

blood component transfusions

and, Feb. 83

clinical manifestations, Feb. 76-

80

clinical syndromes and, Feb. 72

CT in, Feb. 84

cumulative dose and, Feb. 80-

81

diffusing capacity for carbon

monoxide for, Feb. 84

gallium scanning in, Feb. 85

lung volumes and, Feb. 84

mechanisms, Feb. 72-76

mechanisms, direct, Feb. 72-73

mechanisms, indirect, Feb. 73-76

other drug therapy and, Feb. 83

overview, Feb. 72-85

oxygen therapy and, Feb. 82

previous pulmonary disease

and, Feb. 83

radiographs in, chest, Feb. 84-

85

radiotherapy and, Feb. 82

renal failure and, Feb. 83

risk factors, Feb. 80-83

screening tests for, Feb. 83-85

soluble mediators in, Feb. 85

unit dose and, Feb. 81-82

gold salt-induced, Feb. 107-108

clinical features, Feb. 107-108

mechanisms, Feb. 107

heroin-induced, Feb. 103-104

clinical features, Feb. 104

mechanisms, Feb. 103-104

hydrochlorothiazide-induced,

Feb. 109-110

melphalan-induced, Feb. 94-97

clinical features, Feb. 96-97

mechanisms, Feb. 95-96

methadone-induced, Feb. 103-104

clinical features, Feb. 104

mechanisms, Feb. 103-104

methotrexate-induced, Feb. 91-93

clinical features, Feb. 92-93

mechanisms, Feb. 91-92

mitomycin-induced, Feb. 93-94

clinical features, Feb. 93-94

nitrofurantoin-induced, Feb. 101-

103

clinical features, Feb. 102-103

mechanisms, Feb. 101-102

mechanisms, direct, Feb. 101

mechanisms, indirect, Feb.

101-102

nitrosurea-induced, Feb. 89-91

clinical features, Feb. 89-91

mechanisms, Feb. 89

noncytotoxic agents causing, Feb.

111

penicillamine-induced, Feb. 108-109
 clinical features, Feb. 108-109
 previous, and drug-induced pulmonary disease, Feb. 83
 propoxyphene-induced, Feb. 103-104
 clinical features, Feb. 104
 mechanisms, Feb. 103-104
 ritodrine-induced, Feb. 105
 sulfasalazine-induced, Feb. 106
 terbutaline-induced, Feb. 105
 tocainide-induced, Feb. 110-111
 vinblastine-induced, Feb. 97
 vindesine-induced, Feb. 97
 Pump failure, June 338-339

Q

Q-T syndromes, long, July 411-414;
 Nov. 635
 clinical aspects, July 411-412
 recognition, July 411
 treatment, July 412, 414

R

Race: and osteoporosis, Oct. 575
 Radiogrammetry: in osteopenia, Oct. 571
 Radiography, chest
 in pulmonary disease, drug-induced, Feb. 84-85
 in respiratory distress syndrome, adult, Dec. 721
 Radiologic studies: in seizures, Nov. 649-650
 Radionuclide scintigraphy: in mitral valve prolapse, Sept. 511
 Radiotherapy: and drug-induced pulmonary disease, Feb. 82
 Rash
 in dermatomyositis
 on chest wall, May 257
 on hand, May 256
 in erythema multiforme, Apr. 216
 in Stevens-Johnson syndrome, Apr. 216
 in syphilis, Apr. 216

Receptor

adrenergic (see Adrenergic, receptors)
 function in shock, abnormal, June 324-325
 -receptor interactions in shock, June 323

Reentry

abnormal, July 379-381
 clinical implications, July 380-381
 AV, via concealed accessory pathway, July 400
 clinical aspects, July 400
 recognition, July 400
 treatment, July 400
 sinus node, July 391
 clinical aspects, July 391
 recognition, July 391
 treatment, July 391
 tachycardia, AV nodal (see Tachycardia, AV nodal reentry)

Reflex examination: in seizures, Nov. 644

Regurgitation: mitral, in mitral valve prolapse, Sept. 518

Reiter's syndrome: arthritis in, Apr. 213-214

Renal

failure, and drug-induced pulmonary disease, Feb. 83
 syndrome, drug-induced pulmonary, Feb. 80

Renin-angiotensin-aldosterone axis: in shock, June 325-326

Reptiles: causing anaphylaxis, Aug. 455

Respiratory distress syndrome, adult, Dec. 720-728
 incidence rates, Dec. 722
 physiologic derangements in, potential mediators of, Dec. 723
 x-ray in, chest, Dec. 721

Retinopathy: in childhood dermatomyositis, May 280

Ritodrine: inducing pulmonary disease, Feb. 105

Runners: marathon, osteoporosis in, Oct. 565-566

Sarcoma: Kaposi's, in AIDS, Apr. 218
 Scabies: sexually transmitted, Apr. 217-218

Scanning

CT (see Tomography, computed)
 gallium, in drug-induced pulmonary disease, Feb. 85

Scintigraphy: radionuclide, in mitral valve prolapse, Sept. 511

Seizure(s)

absence

atypical, Nov. 631
 clinical presentation, Nov. 630-631

anticonvulsants in (see Anticonvulsants)

atonic, clinical presentation, Nov. 632

benzodiazepines in, Nov. 661
 carbamazepine in, Nov. 658-659

catamenial, Nov. 655-656

cerebellar function in, Nov. 645

clinical presentations, Nov. 626-634

contraceptives and, oral, Nov. 656

cortical function examination in, higher, Nov. 643-644

cranial nerve examination in, Nov. 644

drug interactions and, Nov. 656, 657

drug intoxication causing, Nov. 641

EEG in (see Electroencephalography in seizures)

epileptic, international classification, Nov. 623

ethanol withdrawal causing, Nov. 640-641

ethosuximide in, Nov. 660

evaluation, Nov. 642-650

examination after, Nov. 645-646

examination during, Nov. 645

generalized, primary, clinical presentation, Nov. 630-633

history in, Nov. 642-643

hypnosedative withdrawal causing, Nov. 640-641

intractable, etiology, Nov. 666, 667
 medical management, Nov. 651

metabolic disorders causing, Nov. 641-642

motor examination in, Nov. 644

myoclonic, clinical presentation, Nov. 632

neonatal, clinical presentation, Nov. 632-633

neurologic examination in, Nov. 643-646

in nonepileptic patient, Nov. 639-642

nosology of, Nov. 622-626

partial

clinical presentation, Nov. 627-629

complex, Nov. 623

complex, automatisms in, Nov. 625

complex, clinical presentation, Nov. 628-629

neuroanatomical correlates of, Nov. 627

with secondary generalization, Nov. 629

simple, Nov. 623

simple, clinical presentation, Nov. 627-628

pathologic studies in, clinical, Nov. 650

phenobarbital in, Nov. 660

phenytoin in, Nov. 659-660

physical examination in, Nov. 643

pregnancy and, Nov. 655

primidone in, Nov. 660

radiologic studies in, Nov. 649-650

recordings during, surface, extracellular unit, and intracellular, Nov. 617

reflex examination in, Nov. 644

sensory examination in, Nov. 645

serum concentrations in, Nov. 656-658

single, Nov. 650-661

unprovoked, stratification of recurrence risk after, Nov. 652

tonic, clinical presentation, Nov. 631-632

- valproic acid in, Nov. 660
- Senile osteoporosis, Oct. 559
- Sensory examination: in seizures, Nov. 645
- Sepsis
 - shock in, June 336
 - syndrome, acute, and sexually transmitted diseases, Apr. 215
- Serologic studies: in dermatomyositis/polymyositis, May 266-267
- Serum concentrations: use in seizure management, Nov. 656-658
- Sex: female, at risk for osteoporosis, Oct. 575
- Sexuality: and epilepsy, Nov. 665
- Sexually transmitted
 - diseases, Mar. 133-179; Apr. 193-236
 - arthritis and, Apr. 212-215
 - diagnostic methods, Mar. 134-135
 - etiologic agents, Mar. 134-135
 - extragenital syndromes, Apr. 210-222
 - laboratory data in, Apr. 232-233
 - mononucleosis syndrome and, Apr. 215
 - office approach to, Mar. 133-179; Apr. 193-236
 - oropharyngeal, Apr. 219-220
 - pregnancy and, Apr. 231
 - rash and, diffuse, Apr. 215-218
 - sepsis syndrome and, acute, Apr. 215
- hepatitis
 - B (*see* Hepatitis, B, sexually transmitted)
 - syndrome, acute viral, Apr. 211-212
- scabies, Apr. 217-218
- Shock, June 319-361
 - adrenergic agents in, June, 344-347
 - adrenergic receptors in, June 321-324
 - anaphylactic reactions causing, June 336-337
 - (*See also* Anaphylaxis)
 - anaphylactoid reactions causing, June 336-337
 - atriopeptides in, June 328
 - cardiogenic, June 338-339
 - catecholamines in, June 321-324
 - diagnosis, June 340-341, 342-343
 - distributive, June 336-338
 - eicosanoids in, June 332-333
 - electrolytes in, June 328-330
 - endorphins in, June 333-334
 - enkephalins in, June 333-334
 - environmental influences in, June 334
 - glucagon in, June 326-327
 - hormones in
 - thyroid, June 331-332
 - thyrotropin-releasing, June 331-332
 - thyrotropin-stimulating, June 331-332
 - hypothalamic-pituitary-adrenal axis in, June 330-331
 - hypovolemic, June 335
 - inotropic agents in, June 347-348
 - dosages, June 351
 - obstructive, June 339
 - pharmacotherapy of, June 319-361
 - future, June 349-350
 - historical perspective, June 319-320
 - pressor responsiveness in, June 325-326
 - receptor function in, abnormal, June 324-325
 - receptor-receptor interactions in, June 323
 - renin-angiotensin-aldosterone axis in, June 325-326
 - septic, June 336
 - spinal cord injury causing, June 338
- states
 - physiology, June 320-335
 - specific, etiology and characteristics, June, 335-339
- therapy
 - (*See also* pharmacotherapy above)
 - initial, June 341-349

- Sick sinus syndrome, July 417-418
 clinical aspects, July 417
 recognition, July 417
 treatment, July 417-418
- Signal averaging techniques: in arrhythmias, July 384
- Sinus
 arrest, July 415-417
 clinical aspects, July 415, 417
 ECG, July 416
 recognition, July 415
 treatment, July 417
- arrhythmia (*see* Arrhythmia, sinus)
- bradycardia (*see* Bradycardia, sinus)
- carotid (*see* Hypersensitive carotid sinus syndrome)
- exit block (*see* Block, sinus exit)
- node
 dysfunction, July 414-420
 reentry (*see* Reentry, sinus node)
- sick sinus syndrome (*see* Sick sinus syndrome)
- tachycardia (*see* Tachycardia, sinus)
- Skeleton: natural history of, Oct. 548-550
- Skin
 changes in anaphylaxis, Aug. 457-458
 lesions in dermatomyositis, May 254-259
- Sleep deprivation
 epilepsy and, Nov. 663
 seizures and EEG, Nov. 647
- Smoking: and osteoporosis, Oct. 575
- Social isolation: and epilepsy, Nov. 665
- Soluble mediators: in drug-induced pulmonary disease, Feb. 85
- Spasm
 coronary artery, in mitral valve prolapse, Sept. 517
 infantile, clinical presentation, Nov. 631
- Spinal cord injury: causing shock, June 338
- Staphylococcal pneumonia, Jan. 22-23
- Status epilepticus
 clinical presentation, Nov. 632-633
 generalized convulsive, Nov. 632-633
 management, protocol for, Nov. 663
 management, Nov. 661
 nonconvulsive, Nov. 634
- Steroids
 anaphylaxis due to, Aug. 454
 therapeutic, in anaphylaxis, Aug. 467
- Stevens-Johnson syndrome: rash in, Apr. 216
- Streptococcus*
pneumoniae, Jan. 17-20
pyogenes, Jan. 20
- Stresses: physiologic, and osteoporosis, Oct. 556
- Sudden death: in mitral valve prolapse, Sept. 519-520
- Sulfasalazine: inducing pulmonary disease, Feb. 106
- Supraventricular tachyarrhythmias, July 390-403
- Sympathomimetics: in anaphylaxis, Aug. 465
- Synaptic neurophysiology: of epilepsy, Nov. 615-618
- Syphilis, Apr. 197-199
 arthritis in, Apr. 214
 contacts, Apr. 199
 diagnosis, Apr. 199
 epidemiology, Apr. 198
 microbiology, Apr. 197-198
 physical examination, Apr. 198
 rash in, Apr. 216
 symptoms, Apr. 198
 treatment, Apr. 199
- Systolic
 click, late, in mitral valve prolapse, Sept. 502
 murmur (*see* Murmur)
 time intervals in mitral valve prolapse, Sept. 510

T

- Tachyarrhythmias, July 390
 - supraventricular, July 390-403
 - ventricular, July 403-414
- Tachycardia
 - accelerated AV junctional, July 397-398
 - clinical aspects, July 397
 - recognition, July 397
 - therapy, July 398
 - atrial, July 391-393
 - clinical aspects, July 391, 393
 - ECG, July 392
 - recognition, July 391
 - treatment, July 393
 - AV nodal reentry, July 398-400
 - clinical aspects, July 399
 - recognition, July 398-399
 - treatment, July 399-400
 - sinus, July 390-391
 - clinical aspects, July 390
 - recognition, July 390
 - treatment, July 391
 - ventricular, sustained, July 407-411
 - clinical aspects, July 409
 - ECG, July 408
 - recognition, July 407-409
 - treatment, July 409-411
- Telangiectasias: periungual, in dermatomyositis, May 258
- Terbutaline: inducing pulmonary disease, Feb. 105
- Thromboembolism: in mitral valve prolapse, Sept. 519
- Thyroid hormone: in shock, June 331-332
- Thyrotoxicosis: causing osteopenia, Oct. 591
- Thyrotropin
 - releasing hormone in shock, June 331-332
 - stimulating hormone in shock, June 331-332
- Tocainide: inducing pulmonary disease, Feb. 110-111
- Tomography, computed
 - in osteopenia, Oct. 573
 - in pulmonary disease, drug-induced, Feb. 84

- Torsade de pointes, July 413
- Trabecular bone: remodeling of, Oct. 550-555
- Transfusion: blood component, and drug-induced pulmonary disease, Feb. 83
- Trauma
 - head, and partial epilepsy, Nov. 637-638
 - spinal cord, causing shock, June 338
- Trichomonas vaginalis* (see Trichomoniasis)
- Trichomoniasis, Mar. 137-140
 - contacts, Mar. 140
 - diagnosis, Mar. 138-139
 - epidemiology, Mar. 137-138
 - incidence, Mar. 137-138
 - physical examination, Mar. 138
 - symptoms, Mar. 138
 - treatment, Mar. 139-140
- Trifascicular block, July 422
- Tuberculosis, Jan. 27-29
 - miliary, Jan. 28
- Tumors
 - epilepsy and, partial, Nov. 638
 - osteopenia due to, Oct. 591-592
- Turner's syndrome: and osteoporosis, Oct. 561

U

- Ulcer: genital, Apr. 193-199
- Urethritis
 - Chlamydia trachomatis* negative nongonococcal, Mar. 154-155
 - chlamydial, Mar. 150-154
 - contacts, Mar. 154
 - diagnosis, Mar. 153-154
 - epidemiology, Mar. 150, 152
 - physical examination, Mar. 152-153
 - risk factors, Mar. 150, 152
 - symptoms, Mar. 152-153
 - treatment, Mar. 151, 154
 - gonococcal, Mar. 146-150
 - contacts, Mar. 150
 - diagnosis, Mar. 148-149
 - epidemiology, Mar. 146-147
 - physical examination, Mar. 147-148

Urethritis (*cont.*)

- symptoms, Mar. 147-148
- treatment, Mar. 149-150, 151
- mucopurulent, Mar. 145-155

Urticaria

- in hepatitis B, Apr. 217
- in scabies, sexually transmitted, Apr. 217-218

V

Vaccinations: and dermatomyositis/
polymyositis, May 262-263

Vaginal candidiasis (*see* Candidiasis,
vaginal)

Vaginitis

- nonspecific (*see* Vaginosis, bacterial)
- vulvovaginitis, infectious, Mar. 137-145
- treatment, Mar. 139

Vaginosis, bacterial, Mar. 143-145

- diagnosis, Mar. 143-144
- epidemiology, Mar. 143
- physical examination, Mar. 143
- risk factors, Mar. 143
- symptoms, Mar. 143
- treatment, Mar. 144

Valproic acid: in seizures, Nov. 660

Valve (*see* Mitral valve)

Vascular

- cardiovascular collapse (*see* Anaphylaxis, cardiovascular collapse in)
- cerebrovascular disease and partial epilepsy, Nov. 639
- collagen-vascular diseases and overlap myositis, May 275

Vectorcardiography: in mitral valve
prolapse, Sept. 506-507

Ventricle

- atrioventricular (*see* AV)
- depolarization (*see* Depolarization, ventricular premature)
- fibrillation (*see* Fibrillation, ventricular, sustained)
- intraventricular conduction block (*see* Block, intraventricular conduction)

left, dysfunction, in mitral valve
prolapse, Sept. 517

tachyarrhythmias, July 403-414

tachycardia (*see* Tachycardia,
ventricular, sustained)

Vessels (*see* Vascular)

Video/EEG monitoring: in seizures,

Nov. 648

Vinblastine: inducing pulmonary

disease, Feb. 97

Vindesine: inducing pulmonary dis-

ease, Feb. 97

Virus

hepatitis syndrome, sexually
transmitted acute, Apr. 211-
212

herpes (*see* Herpes)

immunodeficiency, human, Apr.
223-227

pneumonia, Jan. 30-31

Vitamin D: in osteoporosis, Oct. 557

Vulvovaginitis, infectious, Mar. 137-
145

treatment, Mar. 139

W

Walton and Adams classification: of
dermatomyositis/polymyosi-
tis, May 268

Wandering atrial pacemaker (*see*
Pacemaker, wandering atrial)

Warts, genital, Apr. 205-207

diagnosis, Apr. 206

epidemiology, Apr. 205

microbiology, Apr. 205

physical examination, Apr. 205-
206

symptoms, Apr. 205-206

treatment, Apr. 206-207

West's syndrome, Nov. 636

Withdrawal

ethanol, causing seizures, Nov.
640-641

hypnosedative, causing seizures,
Nov. 640-641

X

X-ray (*see* Radiography, chest)

